52 completed, 43 active not recruiting, 20 recruiting, 20 terminated. 82 Phase 2, 69 Phase 1, 13 Phase 3, 3 Early Phase 1.
Follow CTLA-4 Antigen: new trials by email Literature Review of CTLA-4 Antigen trials Research Report on CTLA-4 Antigen
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Adding Anakinra and Tocilizumab to Nivolumab and Ipilimumab for the Treatment of Melanoma Patients 50 Years of Age or Older Anakinra, Biospecimen Collection, Computed Tomography - Melanoma | Phase 1 | Not yet recruiting | University of Southern California | 40 | 2026-11-01 | 2026-09-24 |
| Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer Axitinib, Biospecimen Collection, Bone Scan - Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma | Phase 3 | Recruiting | SWOG Cancer Research Network | 718 | 2026-06-05 | 2026-06-11 |
| VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma | Phase 2 | Recruiting | Mayo Clinic | 18 | 2026-04-21 | 2026-06-05 |
| Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer Biospecimen Collection, Bone Scan, Computed Tomography - Advanced Clear Cell Renal Cell Carcinoma, Advanced Sarcomatoid Renal Cell Carcinoma | Phase 1 | Recruiting | City of Hope Medical Center | 33 | 2026-03-23 | 2026-07-16 |
| Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial Atezolizumab, Bevacizumab, Biospecimen Collection - Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8 | Phase 3 | Recruiting | NRG Oncology | 226 | 2026-02-26 | 2026-08-17 |
| Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer Ipilimumab, Pembrolizumab, Vaccine Therapy - Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8 | Phase 1 | Recruiting | Emory University | 18 | 2025-12-02 | 2026-01-26 |
| INVIGORATE: A Study of QL1706 and Bevacizumab in Advanced First-Line Ovarian Clear Cell Carcinoma QL1706 (bispecific antibody targeting PD-1 and CTLA-4), Bevacizumab, carboplatin - Ovarian Clear Cell Carcinoma | Phase 3 | Recruiting | Tongji Hospital | 226 | 2025-11-15 | 2026-05-18 |
| Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Acral Melanoma, Advanced Cutaneous Melanoma | Phase 2 | Recruiting | Emory University | 99 | 2025-10-29 | 2025-11-12 |
| Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON Trial Biopsy, Biospecimen Collection, Computed Tomography - Locally Advanced Clear Cell Renal Cell Carcinoma, Locally Advanced Sarcomatoid Renal Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | University of Michigan Rogel Cancer Center | 55 | 2025-08-15 | 2026-07-31 |
| Peptide-Pulsed Dendritic Cell Vaccination in Combination With Nivolumab and Ipilimumab for the Treatment of Recurrent and/or Progressive Diffuse Hemispheric Glioma, H3 G34-mutant Dendritic Cell Tumor Peptide Vaccine, Ipilimumab, Leukapheresis - Diffuse Hemispheric Glioma, H3 G34-Mutant | Phase 1 | Withdrawn | Jonsson Comprehensive Cancer Center | 2024-12-01 | 2025-02-24 | |
| Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma Nivolumab, Ipilimumab, Surgical Procedure - Pleural Biphasic Mesothelioma, Pleural Sarcomatoid Mesothelioma | Phase 2 | Recruiting | Alliance for Clinical Trials in Oncology | 26 | 2024-11-27 | 2026-08-05 |
| Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 16 | 2024-07-24 | 2026-10-14 |
| CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer Biospecimen Collection, Bone Scan, CBM588 Capsules - Advanced Clear Cell Renal Cell Carcinoma, Advanced Renal Cell Carcinoma | Phase 1 | Recruiting | Osel, Inc. | 28 | 2024-06-19 | 2024-05-30 |
| Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer Biospecimen Collection, Cabozantinib S-malate, Computed Tomography - Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma | Phase 2 | Suspended | National Cancer Institute (NCI) | 50 | 2024-02-19 | 2026-10-19 |
| Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma Biopsy Procedure, Biospecimen Collection, Cabozantinib - Locally Advanced Extraskeletal Myxoid Chondrosarcoma, Locally Advanced Leiomyosarcoma | Phase 2 | Active not recruiting | National Cancer Institute LAO | 66 | 2023-10-25 | 2026-10-09 |
| Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma Biospecimen Collection, Bone Scan, Computed Tomography - Clear Cell Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma | Phase 1 | Suspended | City of Hope Medical Center | 31 | 2023-10-06 | 2026-10-08 |
| Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma Sarilumab, Ipilimumab Injection, Nivolumab/Relatlimab - Melanoma, Unresectable Melanoma | Phase 2 | Recruiting | NYU Langone Health | 105 | 2023-02-02 | 2026-01-05 |
| Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial Avelumab, Axitinib, Biospecimen Collection - Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8 | Phase 2 | Recruiting | NRG Oncology | 240 | 2023-02-01 | 2026-10-23 |
| A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab Ipilimumab, Nivolumab - BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma | Phase 2 | Terminated | Academic and Community Cancer Research United | 15 | 2023-01-19 | 2026-08-04 |
| Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study Cabozantinib, Ipilimumab, Nivolumab - Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma | Phase 2 | Recruiting | Vanderbilt-Ingram Cancer Center | 54 | 2022-12-06 | 2026-08-19 |
Showing 20 of 150. Sign in to see all of them.
Melanoma (37) · Carcinoma, Renal Cell (16) · Neoplasm Metastasis (10) · Prostatic Neoplasms (10) · Carcinoma, Non-Small-Cell Lung (9) · Leukemia, Myeloid, Acute (8) · Uveal Melanoma (8) · Clear-cell metastatic renal cell carcinoma (7) · Leukemia, Lymphocytic, Chronic, B-Cell (7) · Myelodysplastic Syndromes (7) · Hematologic Neoplasms (6) · Lung Neoplasms (6) · Lymphoma, Non-Hodgkin (6) · Brain Neoplasms (5) · Breast Neoplasms (5)
National Cancer Institute (NCI) (55) · M.D. Anderson Cancer Center (28) · Emory University (6) · City of Hope Medical Center (5) · Jonsson Comprehensive Cancer Center (4) · SWOG Cancer Research Network (4) · Mayo Clinic (3) · Northwestern University (3) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (3) · Academic and Community Cancer Research United (2) · NRG Oncology (2) · OHSU Knight Cancer Institute (2) · Shanghai Cell Therapy Research Institute (2) · University of Washington (2) · Alliance for Clinical Trials in Oncology (1)
United States (140) · Canada (16) · China (4) · Puerto Rico (3) · Australia (2) · Ireland (2) · Denmark (1) · Guam (1) · Netherlands (1)
Frank S Hodi (3) · Sumanta K Pal (3) · A P Chen (2) · Ahmad Tarhini (2) · Amir A Jazaeri (2) · Ana Aparicio (2) · Andrea B Apolo (2) · Evan J Lipson (2) · Haider S Mahdi (2) · Huajun Jin, Ph.D (2) · Jiangtao Wang (2) · Michael Lowe, MD, MA (2) · Qijun Qian, Ph.D (2) · Sapna Patel (2) · Vassiliki Papadimitrakopoulou (2)
PMID 35031545, PMID 18523152, PMID 18974373, PMID 20082117, PMID 25369488, PMID 25649350, PMID 26410619, PMID 27269940, PMID 27410923, PMID 28223062, PMID 28428884, PMID 29246938, PMID 29370992, PMID 29490632, PMID 29784747, PMID 29983880, PMID 30249211, PMID 31401903, PMID 31969335, PMID 31998643, PMID 32192573, PMID 32376721, PMID 32478814, PMID 32503950, PMID 32691060, PMID 32816895, PMID 32850444, PMID 32853585, PMID 32915679, PMID 33125309, PMID 33125909, PMID 33362722, PMID 33603241, PMID 33636027, PMID 33677480, PMID 33720354, PMID 33882143, PMID 33909232, PMID 34032893, PMID 34264316, PMID 34380663, PMID 34413300, PMID 34503735, PMID 34562230, PMID 34716198, PMID 34780125, PMID 34965890, PMID 34980577, PMID 35065057, PMID 35091445
U10CA180820 (10), U10CA180821 (10), U10CA180868 (7), U10CA180888 (7), UM1CA186691 (6), P30CA033572 (5), P30CA138292 (5), U24CA196172 (5), UM1CA186704 (5), P30CA015083 (4), U10CA021115 (4), UM1CA186709 (4), P30CA016672 (3), UM1CA186689 (3), UM1CA186712 (3)